A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)
Status:
Completed
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
This is a 2-part, 4-panel study of MK-5475 in participants with Group 1 pulmonary arterial
hypertension (PAH). Part 1 is a double-blind, randomized, single-ascending dose assessment of
the safety, tolerability and pharmacokinetics (PK) of inhaled MK-5475. Part 2 of this study
is an open-label study and will assess the safety, tolerability, PK and pharmacodynamics of
inhaled MK-5475 at dose determined by results of Part 1 and Period 1 of Part 2 of the study.
There is no formal hypothesis to be tested.